Clinical Trials in Nail Psoriasis: Cross-Sectional Analysis of the Current State of Research.

IF 1.4 Q3 DERMATOLOGY
Skin Appendage Disorders Pub Date : 2025-06-01 Epub Date: 2024-11-12 DOI:10.1159/000542568
Amit Singal, Nina Vijayvargiya, Naeha Pathak, Shari R Lipner
{"title":"Clinical Trials in Nail Psoriasis: Cross-Sectional Analysis of the Current State of Research.","authors":"Amit Singal, Nina Vijayvargiya, Naeha Pathak, Shari R Lipner","doi":"10.1159/000542568","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Nail involvement occurs in approximately 90% of patients with cutaneous psoriasis and in isolation in 5%-10% of patients. There is an unmet need for diagnostic and therapeutic algorithms for nail psoriasis (NP), partially due to limited number of clinical trials.</p><p><strong>Methods: </strong>The ClinicalTrials.gov, the EU, the Australian New Zealand, and the World Health Organization International Clinical Trials Registries were queried for the term \"nail psoriasis\". Trial data characteristics were collected and analyzed.</p><p><strong>Results: </strong>A total of 112 clinical trials were included, with mean trial length 46.7 weeks and mean number of participants 272.7. Medications were most often studied in 97 (86.6%) trials, followed by lasers in 7 (6.3%) trials. NP Severity Index score was the most often studied outcome measure in 91 (84.3%) trials, and only 56 (52.8%) trials assessed adverse events. Only 3 (2.83%) trials included children, and many clinical trials excluded patients aged 65+ and 85+. Results were posted for 46 (41.4%) trials with mean participant age 45.1 years, mean percentage of females of 38.3%, and 87.8% of participants being White.</p><p><strong>Conclusion: </strong>Our findings highlight a need for clinical trials assessing efficacy and long-term therapeutic safety with a broad range of age-groups and increased representation of minorities and female patients.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":"11 3","pages":"232-244"},"PeriodicalIF":1.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136555/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin Appendage Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000542568","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Nail involvement occurs in approximately 90% of patients with cutaneous psoriasis and in isolation in 5%-10% of patients. There is an unmet need for diagnostic and therapeutic algorithms for nail psoriasis (NP), partially due to limited number of clinical trials.

Methods: The ClinicalTrials.gov, the EU, the Australian New Zealand, and the World Health Organization International Clinical Trials Registries were queried for the term "nail psoriasis". Trial data characteristics were collected and analyzed.

Results: A total of 112 clinical trials were included, with mean trial length 46.7 weeks and mean number of participants 272.7. Medications were most often studied in 97 (86.6%) trials, followed by lasers in 7 (6.3%) trials. NP Severity Index score was the most often studied outcome measure in 91 (84.3%) trials, and only 56 (52.8%) trials assessed adverse events. Only 3 (2.83%) trials included children, and many clinical trials excluded patients aged 65+ and 85+. Results were posted for 46 (41.4%) trials with mean participant age 45.1 years, mean percentage of females of 38.3%, and 87.8% of participants being White.

Conclusion: Our findings highlight a need for clinical trials assessing efficacy and long-term therapeutic safety with a broad range of age-groups and increased representation of minorities and female patients.

甲癣的临床试验:研究现状的横断面分析。
导读:大约90%的皮肤型银屑病患者累及指甲,5%-10%的患者单独累及指甲。对于甲癣(NP)的诊断和治疗算法的需求尚未得到满足,部分原因是临床试验数量有限。方法:在ClinicalTrials.gov、欧盟、澳大利亚、新西兰和世界卫生组织国际临床试验登记处查询“指甲型牛皮癣”一词。收集试验数据特征并进行分析。结果:共纳入112项临床试验,平均试验时间46.7周,平均受试者人数272.7人。97项(86.6%)试验最常研究药物,其次是7项(6.3%)试验研究激光。NP严重程度指数评分是91项(84.3%)试验中最常研究的结局指标,只有56项(52.8%)试验评估不良事件。只有3项(2.83%)试验纳入了儿童,许多临床试验排除了65岁以上和85岁以上的患者。结果公布了46项(41.4%)试验,平均参与者年龄为45.1岁,女性平均百分比为38.3%,白人参与者占87.8%。结论:我们的研究结果强调了临床试验评估疗效和长期治疗安全性的必要性,该试验需要广泛的年龄组,并增加少数民族和女性患者的代表性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
10.00%
发文量
69
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信